fg-9041 and 2-amino-3-phosphonopropionic-acid

Recent research has focused on prostaglandins in the central nervous system and their contribution to hyperalgesia and allodynia. This study sought to establish whether neurokinin-1 (NK-1) receptors and glutamate receptors are involved in the hyperalgesic and allodynic effects of spinally administered prostaglandin E2 (PGE2) in rats, and also to determine if the same receptors are involved the hyperalgesia induced by intraplantar administration of zymosan, an inflammatory agent which is known to evoke spinal PGE2 release. Spinal application of antagonists of the NK-1 receptor, the -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate glutamate or metabotropic glutamate receptor significantly attenuated the decrease in mechanical paw withdrawal response thresholds produced by either spinal administration of PGE2 or intraplantar administration of zymosan. The decrease in thermal paw withdrawal response latencies induced by PGE2, but not by zymosan, was significantly attenuated by spinal administration of an N-methyl--aspartate (NMDA) receptor antagonist, an AMPA/kainate receptor antagonist, or a metabotropic glutamate receptor antagonist. Allodynia induced by PGE2 was significantly alleviated by antagonists of NMDA or AMPA/kainate receptors. These results suggest that both PGE2-induced and zymosan-induced mechanical hyperalgesia are mediated in part through activation of NK-1, AMPA/kainate and metabotropic glutamate receptors. PGE2-induced, but not zymosan-induced, thermal hyperalgesia is mediated in part by activation of NMDA, AMPA/kainate and metabotropic glutamate receptors. Activation of both NMDA and AMPA/kainate receptors contribute to PGE2-induced allodynia.

Topics: 2-Amino-5-phosphonovalerate; Alanine; Animals; Dinoprostone; Excitatory Amino Acid Antagonists; Hyperalgesia; Male; Neurokinin-1 Receptor Antagonists; Piperidines; Quinoxalines; Quinuclidines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Glutamate; Receptors, Kainic Acid; Receptors, N-Methyl-D-Aspartate; Receptors, Neurokinin-1; Spinal Cord; Zymosan

We have been using glial cells derived from aged mouse cerebral hemispheres (MACH) at several passages to study the responsiveness of astrocytes to microenvironmental signals in culture. In the present study, we examined the effects of excitatory amino acids on the activity of glutamine synthetase, a marker for astrocytes. MACH glia cell passages 25 to 29 were used. Culture groups were Dulbecco's modified Eagle's medium +10% fetal bovine serum (control); glutamate 100 microM; gamma-amino-3-hydroxy-5-methyl isoxazole-4-propionic acid (AMPA) 50 microM; kainic acid 10 microM; N-methyl-D-aspartate (NMDA) 10 microM. In all treated groups glutamine synthetase activity was significantly higher than in controls. We speculate that this increase represents an enhanced differentiation of immature astrocytes. In a second series, we examined the effects of glutamate receptor antagonists on glutamine synthetase activity as follows. MACH cultures were treated with glutamate 100 microM in combinations with either L(+)-2-amino-3-phosphonopropionic acid (L-AP3; 50 microM); D(-)-2-amino-5-phosphonopentanoic acid (D-AP5; 50 microM) or 6,7-dinitroquinoxaline-2,3-dione (DNQX, 50 microM). The increase in GS activity produced by glutamate was inhibited by the non-selective NMDA receptor antagonist, DNQX, but not by the metabotropic receptor antagonist, L-AP3 or a selective NMDA receptor antagonist, D-AP5. We also found that in cultures treated with glutamate, a number of astrocytes resembled "reactive astrocytes" morphologically. These astrocytes were absent in cultures treated with glutamate+DNQX. The findings provide supportive evidence that astrocytes from aged mouse cerebral hemispheres respond to excitatory amino acids and that this response is mediated by non-NMDA receptor activation.

Topics: 2-Amino-5-phosphonovalerate; Aging; Alanine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Astrocytes; Cell Division; Cells, Cultured; Cerebral Cortex; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Excitatory Amino Acids; Glutamate-Ammonia Ligase; Glutamic Acid; Mice; N-Methylaspartate; Neurotoxins; Quinoxalines; Receptors, N-Methyl-D-Aspartate

Changes on cyclic adenosine monophosphate (cAMP) levels in response to adenosine and glutamate and the subtype of glutamate receptors involved in this interaction were studied in slices of optic tectum from 3-day-old chicks. cAMP accumulation mediated by adenosine (100 microM) was abolished by 8-phenyltheophylline (15 microM). Glutamate and the glutamatergic agonists kainate or trans-D, L-1-aminocyclopentane-1,3-dicarboxylic acid (trans-ACPD) did not evoke cAMP accumulation. Glutamate blocked the adenosine response in a dose-dependent manner. At 100 microM, glutamate did not inhibit the effect of adenosine. The 1 mM and 10 mM doses of glutamate inhibited adenosine-induced cAMP accumulation by 55% and 100%, respectively. When glutamatergic antagonists were used, this inhibitory effect was not affected by 200 microM 6,7-dihydroxy-2,3,dinitroquinoxaline (DNQX), an ionotropic antagonist, and was partially antagonized by 1 mM (RS)-alpha-methyl-4-carboxyphenylglycine [(RS)M-CPG], a metabotropic antagonist, while 1 mM L-2-amino-3-phosphonopropionate (L-AP3) alone, another metabotropic antagonist, presented the same inhibitory effect of glutamate. Kainate (10 mM) and trans-ACPD (100 microM and 1 mM) partially blocked the adenosine response. This study indicates the involvement of metabotropic glutamate receptors in adenylate cyclase inhibition induced by glutamate and its agonists trans-ACPD and kainate.

Topics: Adenosine; Alanine; Animals; Benzoates; Chickens; Cyclic AMP; Excitatory Amino Acid Antagonists; Glutamic Acid; Glycine; In Vitro Techniques; Male; Quinoxalines; Receptors, Metabotropic Glutamate; Superior Colliculi

We previously reported that trophic factors and neurotransmitters in concert regulate survival of cultured cerebellar Purkinje cells. In particular, excitatory amino acid (EAA) transmitters and NGF increased survival, whereas neither alone was effective. In the present studies, we sought to identify molecular mechanisms through which EAAs participate in the survival-promoting interaction. Initially, we characterized the potential role of ionotropic EAA receptors by exposing cultures to the antagonists MK-801, D-2-amino-5-phosphonovaleric acid, and 6,7-dinitroquinoxalinedione. Each increased cell number, suggesting that endogenous ionotropic activity decreased survival. To determine whether metabotropic EAA receptor stimulation modulates survival, the metabotropic agonist ACPD ([1S,3R]-1-aminocyclopentane-1,3-dicarboxylic acid; 1 microM) was tested. ACPD alone had no effect on survival. However, simultaneous exposure to ACPD and NGF significantly increased Purkinje number. Moreover, this increase in survival was blocked by L-AP3 [L(+)-2-amino-3-phosphonopropionic acid; 1 microM], a putative antagonist of certain metabotropic responses. L-AP3 also reduced cell number in the absence of exogenous EAA. Thus, endogenous metabotropic stimulation is normally necessary for survival. In sum, these studies reveal a novel mechanism whereby an excitatory neurotransmitter shapes neural development by simultaneous trophic and regressive actions that are, respectively, mediated by metabotropic and ionotropic EAA receptors.

Topics: 2-Amino-5-phosphonovalerate; Alanine; Animals; Cell Survival; Cells, Cultured; Cyclopentanes; Dizocilpine Maleate; Embryo, Mammalian; gamma-Aminobutyric Acid; Kinetics; Purkinje Cells; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Amino Acid; Receptors, N-Methyl-D-Aspartate

We investigated the hypothesis that stimulation of metabotropic excitatory amino acid receptors in the ventrolateral medulla evokes cardiovascular responses. Thus, (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid [(1S,3R)-ACPD], a selective agonist of metabotropic excitatory amino acid receptors, was microinjected into the rostral or caudal ventrolateral medulla of halothane-anesthetized Sprague-Dawley rats. Microinjections of (1S,3R)-ACPD (100 pmol-1 nmol) into the rostral ventrolateral medulla produced dose-dependent increases in mean arterial pressure (+20 +/- 4 mm Hg by 100 pmol and +35 +/- 2 mm Hg by 1 nmol, p < 0.01 versus artificial cerebrospinal fluid) and integrated splanchnic sympathetic nerve activity (+17 +/- 3% and +46 +/- 4%, respectively, p < 0.01), whereas (1S,3+)-ACPD microinjected into the caudal ventrolateral medulla decreased mean arterial pressure (-28 +/- 2 mm Hg by 100 pmol and -48 +/- 6 mm Hg by 1 nmol, p < 0.01 versus artificial cerebrospinal fluid) and splanchnic sympathetic nerve activity (-24 +/- 4% and -49 +/- 5%, p < 0.01). The blockade of ionotropic excitatory amino acid receptors by the combined injection of 2-amino-7-phosphonoheptanoic acid (200 pmol) and 6,7-dinitroquinoxaline-2,3-dione (200 pmol), which effectively blocked the responses elicited by either N-methyl-D-aspartate (20 pmol) or alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (5 pmol), failed to affect the responses evoked by either (1S,3R)-ACPD (100 pmol) or L-glutamate (2 nmol) microinjected in the rostral and caudal ventrolateral medulla. These results suggest that metabotropic receptors are present and mediate cardiovascular responses evoked by L-glutamate injections into the rostral and caudal ventrolateral medulla.

Topics: 2-Amino-5-phosphonovalerate; Alanine; Amino Acids; Animals; Blood Pressure; Cycloleucine; Dose-Response Relationship, Drug; Drug Combinations; Male; Medulla Oblongata; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Stimulation, Chemical